CNS 7056: Phase I start

This year, Paion will begin a double-blind, placebo- and midazolam-controlled, U.S. Phase I trial to evaluate intravenous CNS 7056 in 40-90 healthy volunteers. The company acquired CNS 7056 earlier th...